Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences is focusing on advancing its core Nano-Pulse Stimulation (NPS) technology in the cardiac and oncology sectors while reducing its dermatology operations. Kevin Danahy has been appointed as the new CEO, with Darrin Uecker becoming Chief Technology Officer. The company has secured a $65 million loan from Robert Duggan, who now serves as Executive Chairman. Pulse aims to refine its strategic focus and expects to announce further progress in its healthcare initiatives within 60 days.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported Q2 2022 revenue of $265,000, a decrease from previous quarters, with notable activities including FDA clearance for expanded energy settings of the CellFX System. The company successfully completed two sales of the system and transitioned four clinics to commercial use, with 43 total conversions. Operating expenses saw a 23% reduction, totaling $14.3 million. The net loss was ($14.0 million) for the quarter. Cash reserves fell to $14.8 million from $47.4 million the previous year, signaling financial challenges.
Pulse Biosciences, Inc. (NASDAQ: PLSE) has received FDA 510(k) clearance for expanded energy settings for its CellFX System in dermatology. This allows U.S. clinicians to offer more customized treatment options for benign lesions. The FDA's expedited review took only 53 days, confirming the new settings' safety and efficacy. The CellFX System, powered by Nano-Pulse Stimulation technology, aims to improve dermatologic outcomes and deliver value through a utilization-based revenue model. The company remains committed to advancing its technology and expanding clinical applications.
Pulse Biosciences, Inc. (Nasdaq: PLSE) will release its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow at 1:30pm PT for investors to discuss the results. The company focuses on bioelectric medicine, offering the CellFX® System, which utilizes Nano-Pulse Stimulation™ technology for treating dermatologic conditions.
Pulse Biosciences (NASDAQ: PLSE) recently announced the granting of equity inducement awards to three new employees. The Compensation Committee approved stock options for a total of 108,500 shares at an exercise price of $2.05, matching the closing stock price on June 15, 2022. The awards are structured mostly with four-year time-based vesting and include performance criteria for one employee. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent within the company.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the successful closing of its rights offering, raising $15 million by selling 7,317,072 units at $2.05 each. Each unit consists of one share of common stock and one warrant for an additional share. The rights offering attracted significant investor interest, exceeding the $15 million limit, leading to a proportionate allocation for over-subscriptions. The gross proceeds may increase to $30 million if all warrants are exercised. As of now, the company has 37,119,352 shares outstanding, effective from the offering.
Pulse Biosciences (NASDAQ: PLSE) announced preliminary results of its rights offering, which expired on May 26, 2022. The final subscription price per Unit was set at $2.05, with each Unit consisting of one common share and one warrant. The offering is expected to generate $15 million in gross proceeds, with an additional potential of $15 million from warrant exercises. Subscription rights not exercised by the expiration date have expired. The results remain preliminary pending finalization by the Subscription Agent.
Pulse Biosciences (Nasdaq: PLSE) has announced an extension for its current rights offering to May 26, 2022, allowing shareholders more time to exercise their rights. The Alternate Price for shares will be based on the volume-weighted average price over five trading days prior to May 23, 2022. This change aims to accommodate reports that some brokers set earlier cut-off dates. The subscription price remains at the lesser of $3.72 or the calculated average price, with previously issued terms still in effect. The rights offering is registered with the SEC.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported Q1 2022 revenue of $444 thousand with system revenue of $367 thousand and cycle units revenue of $77 thousand. The company transitioned 10 Controlled Launch Program participants to commercial use, leading to a total of 39 commercial conversions by quarter-end. Despite a decrease in overall utilization, new leadership has been appointed to enhance strategies. However, GAAP net loss was ($17.3 million), an improvement from ($18.6 million) the previous year, while cash reserves dropped to $12.7 million.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has initiated a rights offering to raise up to $15,000,000. Existing shareholders as of April 25, 2022 will receive non-transferable subscription rights to purchase Units, each comprising one share of Common Stock and a warrant. The initial price is set at $3.72 per Unit, but may adjust based on market conditions. The offering expires on May 23, 2022. This move is part of the company’s shelf registration statement effective since August 21, 2020.